Article By:
ChinaBio® Today
Saturday, March 30, 2024 2:40 PM EDT
South Korea’s AriBio out-licensed China rights for AR1001, an Alzheimer’s disease candidate, in an agreement worth up to $770 million. The company acquiring the asset asked to remain anonymous because of the competition for Alzheimer’s drugs.
The World Has Turned Sunny
I don't really understand why $BGNE was downrated. The news was positive.